Grant✓ Small businesses may apply
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-25-325
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.393
- Status
- posted
- Posted
- Dec 13, 2024
- Closes
- Sep 10, 2027
- Funding instrument
- Cooperative Agreement
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •State governments
- •Private institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Native American tribal governments (Federally recognized)
- •Special district governments
- •Small businesses
- •Independent school districts
- •Public housing authorities/Indian housing authorities
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public and State controlled institutions of higher education
- •City or township governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •County governments
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this NOFO. Extramural research funded under this NOFO may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
Contact
National Institutes of Health · grantsinfo@nih.gov